检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:束家和[1] 周荣耀[1] 钟薏[1] 吴丽英[1]
机构地区:[1]上海中医药大学附属曙光医院肿瘤科,上海200021
出 处:《上海中医药杂志》2011年第5期33-35,45,共4页Shanghai Journal of Traditional Chinese Medicine
摘 要:目的观察益气解毒汤联合CapeOX方案治疗晚期大肠癌的临床疗效和安全性。方法将90例患者随机分为治疗组和对照组(各45例),治疗组采用益气解毒汤联合CapeOX方案治疗,对照组单用CapeOX方案治疗;两组均以21天为1个疗程,共治疗2个疗程;观察临床疗效、中医证候疗效及治疗后生活质量评分、NK细胞、T细胞亚群变化情况;治疗结束1年后,随访观察肿瘤进展时间(TTP)、总生存时间(OS)和1年生存率情况。结果治疗组、对照组临床总有效率(CR+PR)分别为44.44%和37.78%;组间临床疗效比较,差异无统计学意义(P>0.05)。组间临床获益率、肿瘤进展时间、生存时间、1年生存率、中医证候疗效及生活质量(KPS评分)、免疫指标改善情况的差异均有统计学意义(P<0.05)。两组白细胞下降、恶心呕吐发生情况比较,差异有统计学意义(P<0.05)。结论益气解毒汤联合CapeOX方案治疗晚期大肠癌,可控制肿瘤进展,提高患者临床获益率、延长生存期、改善临床症状和生活质量,并能提高免疫功能,减轻化疗的不良反应。Objective To observe the clinical efficacy and safety of "Yiqi Jiedu Decoction" and CapeOX chemotherapy in treating advanced colorectal cancer.Methods Ninety cases were randomly divided into two groups: treatment group in which 45 cases were treated with "Yiqi Jiedu Decoction" and CapeOX chemotherapy,and control group in which 45 cases were treated with CapeOX chemotherapy alone,with a course of 42 days.The clinical effects,TCM syndromes and quality of life score after treatment,NK cells,T cell subsets changes were observed.Time to tumor progression(TTP),overall survival(OS) and 1-year survival rate were observed one year after treatment.Results The total effective rates(CR + PR) in treatment group and control group were 44.44% and 37.78% respectively,with no difference between the two groups(P0.05).There were significant differences in the clinical benefit rate,median time to progression,median survival time,1-year survival rate,TCM symptom improvement rate,quality of life(KPS) and the improvement of immune parameters between the two groups(P0.05).There were also significant differences in leukopenia decrease and occurrence of nausea and vomiting between the two groups(P0.05).Conclusion Combined "Yiqi Jiedu Decoction" and CapeOX chemotherapy can control tumor progression,improve the clinical benefit rate,prolong survival period,improve clinical symptoms and quality of life,immune function,and reduce postchemotherapeutic side effects in the treatment of advanced colorectal cancer.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.15